# Ipamorelin FAQ — Research Literature Questions Answered

> Frequently asked questions about ipamorelin research: mechanism, selectivity, pharmacokinetics, bone and GI studies, human clinical data, regulatory status, WADA classification, and reagent-grade sourcing.

## Research and Mechanism

**Q: What is ipamorelin and how does it work as a research compound?**

Ipamorelin (NNC 26-0161; CAS 170851-70-4) is a synthetic pentapeptide that selectively binds and activates the growth hormone secretagogue receptor type 1a (GHS-R1a). When ipamorelin binds GHS-R1a on pituitary somatotroph cells, it activates Gq/11 G-protein signaling, which triggers intracellular calcium release driving a discrete pulse of GH secretion. GH then stimulates hepatic IGF-1 production mediating downstream anabolic effects. As a research compound, ipamorelin is used to study GHS-R1a pharmacology, pulsatile GH secretion, and GH-dependent downstream biology including bone formation, GI motility, and nitrogen balance. [1][17]

**Q: Why is ipamorelin considered the first selective growth hormone secretagogue?**

Before ipamorelin's characterization in 1998, GHRP-class compounds such as GHRP-2 and GHRP-6 stimulated GH release but also activated the corticotroph axis (raising ACTH and cortisol). Ipamorelin does not meaningfully elevate ACTH or cortisol even at doses 200-fold above its GH-releasing ED50 in rats, and does not activate prolactin or TSH secretion. [1] A 2020 review designated ipamorelin the "prototypical selective GHS." [17]

**Q: What does the peer-reviewed research show about ipamorelin's effects on bone and muscle?**

Three primary rodent studies examined skeletal effects. Subcutaneous ipamorelin at 18–450 mcg/day for 15 days in adult female rats produced a dose-dependent increase in longitudinal bone growth rate from 42 to 52 mcm/day, without changes in circulating IGF-1. [2] Continuous infusion at 0.5 mg/kg/day for 12 weeks significantly increased tibial and vertebral bone mineral content via periosteal expansion. [4] In glucocorticoid-treated rats, 100 mcg/kg three times daily for three months produced a four-fold increase in periosteal bone formation rate and significant recovery of muscle maximum tetanic tension. [3] All three studies were conducted in rodents; no controlled human studies of ipamorelin's effects on bone or muscle have been published.

**Q: Has ipamorelin been studied in human clinical trials?**

One Phase 2 randomized, double-blind, placebo-controlled clinical trial has been published. Beck et al. (2014; NCT00672074) enrolled 114 adults undergoing bowel resection and administered ipamorelin at 0.03 mg/kg intravenously twice daily for up to seven post-operative days. [10] The compound was well tolerated (adverse events 87.5% ipamorelin vs 94.8% placebo). Time to first tolerated meal was 25.3 hours vs 32.6 hours placebo, a 7.3-hour improvement that did not reach statistical significance (p=0.15). [10]

**Q: What are the pharmacokinetics of ipamorelin?**

In healthy human volunteers (IV administration), ipamorelin shows a terminal half-life of approximately 2 hours, clearance of 0.078 L/h/kg, and volume of distribution at steady-state of 0.22 L/kg. GH peaks at approximately 40 minutes post-dose and returns to negligible levels within 2–3 hours. Pharmacokinetics are linear (dose-proportional). [12] In rats, plasma clearance is approximately five-fold lower than GHRP-6, with 60–80% of an administered dose recovered as intact peptide. [11] Intranasal bioavailability in rats is approximately 20%. [11]

## Regulatory and Sourcing

**Q: What is ipamorelin's regulatory status as of 2025?**

Ipamorelin is not approved by the FDA, EMA, or any other major regulatory agency for any human therapeutic indication. The FDA 503A compounding nomination (docket FDA-2024-N-4188) was withdrawn by the nominator in September 2024, removing it from consideration for compounding pharmacy use. [16]

**Q: Is ipamorelin prohibited in sport?**

Yes. Ipamorelin is classified as a prohibited substance under the WADA Prohibited List S2 — Peptide Hormones, Growth Factors, Related Substances and Mimetics, subcategory S2.2.4 Growth Hormone Secretagogues. The prohibition applies both in-competition and out-of-competition. No Therapeutic Use Exemption is available for competitive athletes. [18]

**Q: How does ipamorelin differ from GHRP-2 and GHRP-6?**

All three compounds are GHS-R1a agonists that stimulate pulsatile GH release. GHRP-2 has the highest GHS-R1a binding affinity (~0.3–0.4 nM Ki) but stimulates ACTH/cortisol and prolactin secretion. GHRP-6 shows similar GH-releasing potency to ipamorelin but also activates appetite via CD36 binding and stimulates cortisol release. Ipamorelin binds GHS-R1a at approximately 1.0–1.5 nM Ki but does not significantly stimulate ACTH, cortisol, prolactin, or TSH even at doses 200-fold above its GH-releasing ED50. [1]

**Q: What purity specifications should researchers look for when sourcing ipamorelin?**

Research-grade ipamorelin should meet ≥98% purity by reversed-phase HPLC, with molecular weight confirmed by LC-MS at 711.86 Da (C38H49N9O5). [16] A complete Certificate of Analysis should include lot number, HPLC purity percentage, amino acid analysis confirming the pentapeptide sequence, MS identity confirmation, and storage specifications. Third-party COA documentation is preferred. Lyophilized powder should be stored at −20°C long-term. [16]

**Q: What are the limitations of the current ipamorelin research literature?**

Several limitations characterize the ipamorelin evidence base. Virtually all dose-response and mechanistic data come from rodent models, with the single controlled human study (Beck 2014) not meeting its primary efficacy endpoint. [10] Long-term safety data for repeated GH pulse stimulation have not been characterized in humans; theoretical concerns include receptor desensitization and GH-independent adiposity effects documented in mice. [6] The FDA 503A compounding nomination was withdrawn in September 2024. [16] Research-grade commercial preparations vary widely in quality. [16]

**Q: What are the reported GH-independent effects of ipamorelin?**

Lall et al. (2001) found that ipamorelin and GHRP-6 administered to GH-deficient and GH-intact mice elevated fat pad weights, serum leptin, and food intake via hypothalamic GHS-R1a activation, independently of changes in circulating GH. [6] This is mechanistically significant: chronic GHS-R1a agonism may increase adiposity through a GH-independent pathway.

**Q: Has ipamorelin been studied for cancer-related weight loss?**

A 2024 study in Physiology & Behavior examined ipamorelin and anamorelin in a ferret cisplatin-induced weight loss and emesis model. [15] Intraperitoneal ipamorelin inhibited cisplatin-induced weight loss by approximately 24% during the delayed phase (48–72 hours post-cisplatin). Ipamorelin did not demonstrate significant anti-emetic effects, indicating a peripheral weight-preservation mechanism. This is preclinical data in a ferret model; no clinical trials of ipamorelin in cancer-related weight loss have been published. [15]

**Q: What is the ipamorelin CJC-1295 research combination rationale?**

CJC-1295 is a GHRH receptor agonist (activating the cAMP/PKA pathway on somatotrophs), while ipamorelin activates GHS-R1a (the Ca2+/Gq pathway). Because the two compounds act through different intracellular pathways on the same pituitary somatotroph, synergistic GH pulse amplification has been proposed. [1][17] No peer-reviewed ipamorelin + CJC-1295 combination study has been published.

**Q: Does ipamorelin need to be reconstituted before research use?**

Research-grade ipamorelin is distributed as a lyophilized powder. Before research use, it requires reconstitution in an appropriate solvent — bacteriostatic water is the standard for in vitro and in vivo peptide research. Once reconstituted, the solution should be stored at 4°C and used within a short timeframe. Repeated freeze-thaw cycles should be avoided. [16]

## References

[1] Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561.
[2] Johansen PB et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research. 1999;9(2):106-113.
[3] Andersen NB et al. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation. Growth Hormone & IGF Research. 2001;11(5):266-272.
[4] Svensson J et al. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. Journal of Endocrinology. 2000;165(3):569-577.
[6] Lall S et al. GH-independent stimulation of adiposity by GH secretagogues. Biochemical and Biophysical Research Communications. 2001;280(1):132-138.
[10] Beck DE, Sweeney WB, McCarter MD. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin. International Journal of Colorectal Disease. 2014;29(12):1527-1534.
[11] Johansen PB et al. Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues. Xenobiotica. 1998;28(11):1083-1091.
[12] Gobburu JV et al. Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin in Human Volunteers. Pharmaceutical Research. 1999;16(9):1412-1416.
[15] GHS-R1a agonists anamorelin and ipamorelin inhibit cisplatin-induced weight loss in ferrets. Physiology & Behavior. 2024;284:114644.
[16] U.S. FDA. Bulk Drug Substance Nomination: Ipamorelin acetate / Ipamorelin free base (FDA-2024-N-4188). 2024.
[17] Ishida J et al. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications. 2020;3(1):25-37.
[18] Sport Integrity Australia. Ipamorelin (Pentapeptide) Substance Information. 2025.

---

For research purposes only. Not for human consumption. This site does not sell any product and is not affiliated with any vendor.